
The United States market has experienced a flat week, yet it has shown an impressive 9.2% increase over the past year, with earnings projected to grow by 17% annually. In this environment, identifying growth companies with substantial insider ownership can be advantageous as it often signals confidence in the company's potential and alignment of interests between insiders and shareholders.
| Name | Insider Ownership | Earnings Growth |
| Upstart Holdings (UPST) | 14.0% | 70.2% |
| Standard Nuclear (STDN) | 20.6% | 64.2% |
| Sable Offshore (SOC) | 11.3% | 71.3% |
| Precigen (PGEN) | 11.7% | 57.6% |
| Nu Holdings (NU) | 23.1% | 21.3% |
| Karman Holdings (KRMN) | 13.5% | 56.3% |
| Himax Technologies (HIMX) | 29.1% | 70.2% |
| Figure Technology Solutions (FIGR) | 21.4% | 33.1% |
| Dave (DAVE) | 16.6% | 24.1% |
| Almonty Industries (ALM) | 10.8% | 58.3% |
Let's review some notable picks from our screened stocks.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Quantum Computing Inc. is an integrated photonics company that supplies quantum machines to commercial and government markets in the United States, with a market cap of $1.45 billion.
Operations: The company generates revenue from its Software & Programming segment, amounting to $9.82 million.
Insider Ownership: 11.2%
Earnings Growth Forecast: 55.9% p.a.
Quantum Computing Inc. is poised for significant growth, with revenue projected to expand at 59.2% annually, outpacing the US market. The company is expected to achieve profitability within three years, surpassing average market growth rates. Recent strategic alliances and product advancements, such as the Dirac-3S quantum optimization machine and collaborations in pharmaceuticals and quantum security, highlight its expanding commercial footprint. Despite past losses, Quantum Computing Inc.'s innovative technologies position it well for future opportunities in various sectors.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company involved in the development, manufacturing, marketing, and distribution of generics, injectables, biosimilars, and specialty branded pharmaceutical products across the United States, India, Ireland and other international markets with a market cap of $7.32 billion.
Operations: The company's revenue is primarily derived from its Affordable Medicines segment at $1.81 billion, followed by Avkare at $732.28 million, and Specialty products contributing $574.73 million.
Insider Ownership: 38.2%
Earnings Growth Forecast: 30.9% p.a.
Amneal Pharmaceuticals demonstrates significant growth potential with earnings projected to increase by 30.9% annually, surpassing the US market average. Despite slower revenue growth at 8.9% per year, recent FDA approval for lanreotide injection and raised earnings guidance underscore its expansion efforts. Insider activity shows more shares bought than sold recently, reflecting confidence in its prospects. However, financial health concerns exist due to insufficient coverage of interest payments by earnings and large one-off items impacting results.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Ramaco Resources, Inc. is involved in the development, operation, and sale of metallurgical coal with a market cap of $450.52 million.
Operations: The company generates revenue primarily from the metallurgical coal segment, which accounted for $515.42 million.
Insider Ownership: 11.3%
Earnings Growth Forecast: 109.4% p.a.
Ramaco Resources is positioned for substantial growth, with revenue forecasted to increase by 21.9% annually, outpacing the US market. Despite a recent net loss of US$15.42 million in Q2 2026 and reduced production guidance, strategic alliances in critical minerals could bolster future prospects. The company trades significantly below its estimated fair value but faces challenges as debt coverage by operating cash flow remains insufficient. Recent board changes include the departure of Joe Manchin to focus on other initiatives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com